Home » News » August 2017

August, 2017

Rheinmetall Defence Australia $80m R&D project

August 18th, 2017

Rheinmetall Defence Australia (RDA) has announced a five year research and development plan to invest $80 million into product and technology development as part of the AIC program for Land 400 Phase 2. In addition to this, there is also scope for a further $120 million in funding should the company be successful in Phase 3 of Land 4. Rheinmetall is a powerful and internationally successful army technology supplier and longstanding partner of the armed forces, with a mission to […]

Read More

Rix’s Creek Pty Limited; Bloomfield Collieries Pty Limited v Innovation Australia [2017] AATA 645

May 26th, 2017

Introduction The case Rix’s Creek Pty Limited; Bloomfield Collieries Pty Limited and Innovation Australia [2017] AATA 645, refers to two related mining companies which registered and claimed for the R&D Tax Concession for the years 2008 to 2012. After reviews were conducted on the claimed activities, Innovation and Science Australia found that the majority of the activities were not eligible for the R&D assistance. The respective companies opposed this decision and applied to the Administrative Appeals Tribunal for an independent […]

Read More

The R&D Tax Incentive Makes It Through Federal Budget Cuts Unharmed

May 10th, 2017

As a relief to many, no adverse changes were proposed to the R&D Tax Incentive within the Federal Budget delivered by the government on May 9. The R&D Tax Incentive has played an important role in attracting investment to Australia, particularly in knowledge intensive industries. It has also provided small business valuable working capital in the early stages of their life cycle. The government is still yet to respond to the Ferris, Finkel & Fraser review which recommended potential adverse […]

Read More

Biotech Industry Wary of Proposed Changes to R&D Tax Incentive

May 2nd, 2017

The Australian biotech industry has concerns about an overhaul of the R&D tax incentive scheme, which could involve eligibility restrictions and cuts. The government has proposed capping R&D tax refunds at $2 million, which could be realised in this month’s federal budget. The uncertainty has already impacted the sector, with both Australian and international companies reconsidering doing clinical trials here. As Chris Nave, managing director of Brandon Capital Partners commented, “$2 million isn’t worth the cost of setting up an […]

Read More

Categories

Archives